Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide

Oncology

Volumn 56, Issue 1, 1999, Pages 28-35

  Koumakis, George ^a   Vassilomanolakis, M ^a   Barbounis, V ^a   Hatzichristou, E ^a   Demiri, S ^a   Plataniotis, G ^a   Pamouktsoglou, F ^a   Efremidis, A P ^a,b  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

G CSF administration; Optimal timing

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BONE PAIN; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CYTOPENIA; DISEASE DURATION; DRUG COST; DRUG USE; FEVER; HUMAN; INCIDENCE; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LEUKOPENIA; LUNG CANCER; MYALGIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; RASH; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032945380     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011926     Document Type: Article

References (20)

1. Gabrilove JL, Jakubowski A: Granulocyte colony stimulating factor: Preclinial and clinical studies. Hematol Oncol Clin North Am 1989;3: 427-440.
2. Glaspy JA, Golde DW: Clinical applications of the myeloid growth factors. Semin Hematol 1989;26:14-17.
3. Souza LM, Boone TC, Gabrilove JL, et al: Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science 1986;232:61-65.
4. Weisbart RH, Gasson JC, Golde DW: Colony stimulating factors and host defense. Ann Intern Med 1989;110:297-303.
5. Schmidberger H, Hess CF, Hoffman W, et al: Granulocyte colony stimulating factor treatment of leukopenia during fractionated radiotherapy. Eur J Cancer 1993;29A:1927-1931.
6. MacManus MP, McCormick D, Trimble A, et al: Value of granulocyte colony stimulating factor in radiotherapy induced neutropenia: Clinical and laboratory studies. Eur J Cancer 1995; 31A(3):302-307.
7. Bronchud MH, Scarffe JH, Thatcher N, et al: Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987;56:809-813.
8. Morstyn G, Souza LM, Keech J, et al: Effect of granulocyte colony stimulating factor on neutropenia induced by cytoxic chemotherapy. Lancet 1988;i:667-672.
9. Gabrilove JL, Jakubowski AJ, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 1988;318: 1414-1422.
10. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991;325:164-170.
11. Fukuoda M, Masuda N, Takada M, et al: Dose intensive chemotherapy in extensive stage small cell lung cancer. Semin Oncol 1994; 21(suppl 1):43-47.
12. Gillio AP, Bonilla MA, Potter GK, et al: Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic reconstitution after autologous bone marrow transplantation in primates. Transplant Proc 1987;19: 153-156.
13. Peters WP, Kurtzberg J, Atwater S, et al: Comparative effects of rHuG-CSF and rHuGM-CSF on hematopoietic reconstitution and granulocyte function following high dose chemotherapy and autologous bone marrow transplantation (abstract). Blood 1988;72:130a.
14. Taylor K, Jagannath S, Spitzer G, et al: Recombinant human granulocyte colony stimulating factor hastens granulocyte recovery after high dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 1989;7:1791-1799.
15. Stahel RA, Lost LM, Cerny T, et al: Randomized study of recombinant human granulocyte colony-stimulating factor after high dose chemotherapy and autologous bone marrow transplantation for high risk lymphoid malignancies. J Clin Oncol 1994;12:1931-1938.
16. Morstyn G, Campbell L, Lieschke G, et al: Treatment of chemotherapy induced neutropenia by subcutaneously administered granulocyte colony stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 1989;7:1554-1562.
17. Welte K, Bonilla MA, Gillio AP, et al: Recombinant human granulocyte colony-stimulating factor: Effects of hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 1987;165:941-948.
18. Meisenberg BR, Davis TA, Melaragno AJ, Stead R, Monroy RL: A comparison of therapeutic schedules for administering granulocyte colony-stimulating factor to non human primates after high dose chemotherapy. Blood 1992;79:2267-2272.
19. Butler RD, Waites TM, Lamar RE, Hainsworth JD, Greco FA, Johnson DH: Timing of G-CSF administration during intensive chemotherapy for breast cancer (abstract). Am Soc Clin Oncol 1992;11:1411.
20. Fukuda M, Nakato M, Kinoshita A, et al: Optimal timing of G-CSF administration in patients receiving chemotherapy for non-small cell lung cancer (NSCLC) (abstract). Am Soc Clin Oncol 1993;12:1549.